Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study.

Name: Kaimen Rigor review — Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study.
Item: Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study.
Rating: 96
Author: Alpha1

Choueiri TK, Albiges L, Barthélémy P, Iacovelli R, Emambux S, Molina-Cerrillo J, Garmezy B, Barata P, Basu A, Bourlon MT, Moon H, Ratta R, McKay RR, Chehrazi-Raffle A, Hammers H, Heng DYC, Braendle E, Beckermann KE, McGregor BA, Motzer RJ

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 3.25★ (Adequate), 0 critical, 2 high issues for “Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 16, 2026

Read alongside

Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study.

Read full text (PMC)

DOI

10.1016/S0140-6736(24)01758-6

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/ee4f5f28-0e77-4f18-86da-31516ecc71e4" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/ee4f5f28-0e77-4f18-86da-31516ecc71e4/badge" alt="Kaimen Rigor review — 3.25★ (Adequate), 0 critical, 2 high issues for “Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

9a0763386a75ce5629a0eec14f087c9cdff8e953ab885783d3488ede8043a558

Verify via API

Issued Aug 16, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study.

Paper source

Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 16, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

3.25 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 2 reported means were read, and their group size is not stated where the values are printed. These checks need the count the mean was averaged over, so none was performed.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary endpoint is progression-free survival (PFS), a surrogate for overall survival. The paper does not demonstrate target engagement at the tested dose (no PK/PD data) and does not cite validated evidence linking PFS to overall survival in this specific post-ICI RCC setting. The efficacy claim is based on PFS, which is a surrogate.
“Primary endpoint was PFS by independent radiology review.”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The primary analysis shows no benefit of the combination (HR 1.10, p=0.49). The claim of tivozanib monotherapy efficacy is based on a median PFS of 7.4 months, but no anchor to a minimal clinically important difference or comparison to a clinically meaningful threshold is provided. The effect size is not explicitly anchored as clinically meaningful.
“mPFS was 5·7 months (95%CI, 4·04–7·43) with tivozanib–nivolumab and 7·4 months (5·55–9·23) with tivozanib (HR, 1·10; 95%CI, 0·84–1·43; p=0·49).”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 302OverreachOverstated conclusions 03AuthenticityNone found 104DisclosureReporting gaps 05AvailabilityNone found 06Copyedit5 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted phase 3 randomized trial with rigorous design, clear reporting of ethics, demographics, and statistical methods. The main weakness is the vague data sharing statement, and minor omissions include lack of statistical software identification and explicit reporting guideline adherence. The copyedit pass found only minor typographical and consistency issues.

Both reviewers independently scored all eight dimensions and agreed on every status; no divergence required reconciliation. The statistics verification recomputed only 2 tests (those with test statistics/CI), so the broader statistical correctness is not fully verified. The citation check found no retracted or unresolved references.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.

Overstated conclusions

3 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

4 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

1 finding · worst medium

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

The introduction cites TIVO-3 and CONTACT-03, acknowledging their strengths and limitations, and builds a rationale for testing tivozanib with or without nivolumab in the post-ICI setting. The hypothesis follows logically from the cited evidence, and the paper addresses gaps in prior research, such as differences between anti-PD-1 and anti-PD-L1 rechallenge.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior research on ICI rechallenge and tivozanib, and provides a logical rationale for the study.

Evidence

paraphrase[Introduction, paragraph 1-3]

“The negative outcome of CONTACT-03 left several questions unanswered, such as potential differences between anti–PD-1 and anti–PD-L1 therapies in the rechallenge setting...”

“To further explore retreatment with ICI we conducted a study comparing tivozanib with or without nivolumab in patients with mRCC who have progressed following 1 or 2 lines of therapy in the post-ICI setting.”

IntroductionFind in source

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise by citing prior research on ICI rechallenge and tivozanib efficacy, and provides a logical rationale for the study.

Evidence

“The TIVO-3 study was the first phase 3 study to prospectively define a study population with prior ICI (26% of patients) and demonstrated an improvement in progression-free survival (PFS) with tivozanib compared with sorafenib (median PFS, 7·3 months vs 5·1 months, respectively; HR, 0·55; p=0·028) in the subgroup that received prior ICI.”

Introduction ¶1Find in source

“The negative outcome of CONTACT-03 left several questions unanswered, such as potential differences between anti–PD-1 and anti–PD-L1 therapies in the rechallenge setting, whether outcomes of ICI rechallenge would be impacted if a non-ICI were used before subsequent ICI treatment, and whether VEGFR TKI dosing and TKI selectivity would impact tolerability or efficacy of combination therapy.”

Introduction ¶3Find in source

Randomization method (complete permutated block design) and unit (patient) are described. Blinding is not applicable as the trial is open-label, but the rationale is stated. Power analysis is reported with sample size and hazard ratio assumptions. Inclusion/exclusion criteria are detailed. Outlier handling is addressed through ITT and safety populations. Controls are inherent in the comparator arm. Independent replication is not applicable for a single pivotal trial.

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous with clear randomization, stratification, and a pre-specified statistical analysis plan, though it is open-label.

Evidence

“Randomisation was performed using a randomisation trial supply management system. Once the strata were identified, patients were randomly assigned to a treatment arm within the strata using a complete permutated block design in an unblinded fashion (open label).”

MethodsFind in source

“The planned sample size of 326 patients with 191 events was intended to detect an improvement of 4 months or 50% and a hazard ratio of 0.67 with respect to the primary endpoint of PFS per IRR”

Statistical analysisFind in source

“Eligible patients were ≥18 years of age, with measurable disease per Response Evaluation Criteria in Solid Tumours (RECIST) version 1·1, Eastern Cooperative Oncology Group performance status 0 or 1, life expectancy ≥3 months, and adequate recovery from AEs related to prior therapy”

MethodsFind in source

PASSReviewer 2· 90% conf

The study design is rigorous for a phase 3 trial, with clear randomization, stratification, and a pre-specified primary endpoint, though it is open-label.

Evidence

MethodsFind in source

“The planned sample size of 326 patients with 191 events was intended to detect an improvement of 4 months or 50% and a hazard ratio of 0.67 with respect to the primary endpoint of PFS per IRR”

Statistical analysisFind in source

Sex, age, and race are reported in Table 1. Age and health status (ECOG) are reported. Demographics are comprehensive. Species/strain and housing are not applicable for a human trial. Sex justification is not applicable as both sexes are enrolled.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and clinical characteristics are well reported, including sex, age, and race, which are adequate for a human trial.

Evidence

“Age (years) Mean (range) | 63·3 (37–87) | 62·2 (33–82) | | Sex, n (%) Male Female | 125 (73) 46 (27) | 134 (78) 38 (22)”

Table 1Find in source

“Race, n (%) White Asian Black or African American Not reported, other, or missing | 112 (65) 1 (<1) 2 (1) 56 (33) | 107 (62) 0 8 (5) 57 (33)”

Table 1Find in source

PASSReviewer 2· 90% conf

Biological variables are well reported for a human trial, including sex, age, and demographics.

Evidence

“Sex, n (%) Male Female | 125 (73) 46 (27) | 134 (78) 38 (22) |”

Table 1Find in source

“Race, n (%) White Asian Black or African American Not reported, other, or missing | 112 (65) 1 (<1) 2 (1) 56 (33) | 107 (62) 0 8 (5) 57 (33) |”

Table 1Find in source

The study protocol was approved by independent review boards or ethics committees at each site. Written informed consent was obtained from all patients. Regulatory compliance with ICH-GCP and Declaration of Helsinki is stated.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approvals and consent are adequately reported, including IRB approval and written informed consent.

Evidence

“the study protocol and all amendments were approved by independent review boards or ethics committees at each study site.”

MethodsFind in source

“All patients provided written informed consent prior to any screening or study procedures.”

MethodsFind in source

“each investigative facility agreed to follow all applicable local regulatory requirements and to perform the study in accordance with the Good Clinical Practice Guidelines of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and the Declaration of Helsinki.”

MethodsFind in source

PASSReviewer 2· 90% conf

Ethical approvals and consent are adequately reported.

Evidence

“the study protocol and all amendments were approved by independent review boards or ethics committees at each study site.”

MethodsFind in source

“All patients provided written informed consent prior to any screening or study procedures.”

MethodsFind in source

Tivozanib and nivolumab are named with manufacturers (Aveo and BMS) and dosing regimens. No bench reagents or cell lines are used, so those criteria are not applicable. Software tools are not described in detail, but the statistical software is not specified; however, this is not a key resource for a clinical trial.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedNOT REPORTED

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational products (tivozanib and nivolumab) are identified with manufacturer and dosing, which is adequate for a drug trial.

Evidence

“Tivozanib was provided by the study sponsor (Aveo Pharmaceuticals, Inc.; Boston, MA, USA), and nivolumab was provided by Bristol Myers Squibb (Princeton, NJ, USA).”

MethodsFind in source

“patients in arm A received tivozanib at an oral dose of 0·89 mg QD for 21 consecutive days followed by a 7-day rest period; nivolumab was administered on day 1 of each cycle at an intravenous (IV) dose of 480 mg.”

MethodsFind in source

PASSReviewer 2· 90% conf

The investigational products are adequately identified, and no other key biological resources are used.

Evidence

“Tivozanib was provided by the study sponsor (Aveo Pharmaceuticals, Inc.; Boston, MA, USA), and nivolumab was provided by Bristol Myers Squibb (Princeton, NJ, USA).”

MethodsFind in source

Tests are named (stratified log-rank, Cochran-Mantel-Haenszel). Assumptions are handled by design (stratified analysis). Exact p-values are reported (e.g., p=0.49). Effect sizes with CIs are reported. Statistical software is not identified, but this is a minor omission. Data presentation includes Kaplan-Meier curves and forest plots. Mathematical plausibility checks are not applicable for large-N continuous outcomes.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedNOT REPORTED

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and confidence intervals reported.

Evidence

“Treatment arms were compared using a stratified log-rank test with a two-sided 5% significance level.”

Statistical analysisFind in source

“The stratified hazard ratio was 1·10 (95% CI, 0·84–1·43; p=0·49)”

Results ¶2Find in source

“mPFS was 5·7 months (95%CI, 4·04–7·43) with tivozanib–nivolumab and 7·4 months (5·55–9·23) with tivozanib (HR, 1·10; 95%CI, 0·84–1·43; p=0·49).”

Results ¶2Find in source

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and confidence intervals reported.

Evidence

“Treatment arms were compared using a stratified log-rank test with a two-sided 5% significance level.”

Statistical analysisFind in source

“The stratified hazard ratio was 1·10 (95% CI, 0·84–1·43; p=0·49)”

Results ¶2Find in source

The data sharing statement says 'qualified researchers may request access to individual patient-level clinical data through a data request platform' but does not name the platform or provide conditions. This is reported_but_inadequate. Repository deposit and accession numbers are not applicable for patient-level data. Code sharing is not applicable as no bespoke code is mentioned.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 80% conf

A data sharing statement is present but vague, lacking specific platform details or conditions.

Evidence

“For eligible studies, qualified researchers may request access to individual patient-level clinical data through a data request platform.”

Data availabilityFind in source

WARNReviewer 2· 80% conf

A data sharing statement is present but vague, lacking a specific platform or conditions.

Evidence

“For eligible studies, qualified researchers may request access to individual patient-level clinical data through a data request platform.”

Data availabilityFind in source

The trial is registered (NCT04987203). Limitations are explicitly discussed, including open-label design and reduced tivozanib dose. Conclusions are proportional to the evidence, noting the primary endpoint was not met. Funding and COI statements are provided. Reporting guideline (CONSORT) is not explicitly mentioned, but the paper follows standard reporting.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineNOT REPORTED

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The manuscript is transparent with trial registration, limitations discussed, and proportional conclusions.

Evidence

“The trial is registered with ClinicalTrials.gov (https://clinicaltrials.gov/) : NCT04987203 (https://clinicaltrials.gov/ct2/show/NCT04987203) .”

Statistical analysisFind in source

paraphrase[Discussion, paragraph 5]

“There are, however, several limitations of the study to be recognized: (1) The reduced dose of tivozanib used to manage the potential increased toxicity in the combination arm. ... (2) The open-label study design is in principle more vulnerable to patient bias and placebo effects due to lack of blinding for both patients and investigators.”

“Funding Aveo Pharmaceuticals, Inc.”

FundingFind in source

PASSReviewer 2· 90% conf

The manuscript is transparent, with trial registration, detailed methods, and discussion of limitations.

Evidence

“The trial is registered with ClinicalTrials.gov (https://clinicaltrials.gov/) : NCT04987203 (https://clinicaltrials.gov/ct2/show/NCT04987203) .”

Statistical analysisFind in source

“There are, however, several limitations of the study to be recognized: (1) The reduced dose of tivozanib used to manage the potential increased toxicity in the combination arm. This choice may have impacted the efficacy reflected by the numerically lower median PFS in the combination arm. (2) The open-label study design is in principle more vulnerable to patient bias and placebo effects due to lack of blinding for both patients and investigators.”

Discussion ¶5Find in source

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 21 references by DOI: 19 verified — 2 no DOI (shown, not verified).

1 data/code link checked; 1 live.

Copyediting

5 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 5 minor suggestions below.

5 copyedit issues flagged: mostly consistency, typo, clarity.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust and transparent, with only minor reporting gaps (vague data sharing, unnamed software, no explicit CONSORT statement) and minor copyedit issues. An informed reader should weigh the open-label design and reduced tivozanib dose as limitations, but these are disclosed. No erratum is warranted for the identified issues, though the data sharing statement could be clarified in a future update.

1.
HIGHdata code
In the Data sharing statement, specify the data request platform (e.g., Vivli, YODA) and the conditions for access (e.g., proposal review, timeframe).
The current statement is vague and does not meet the standard for data availability, which is a common reviewer concern.
2.
HIGHstatistics
In the Methods, Statistical analysis, identify the statistical software and version used (e.g., SAS 9.4, R 4.0).
Naming the software improves reproducibility and is expected in clinical trial reporting.
3.
MEDIUMreporting
In the Methods or end of manuscript, state adherence to CONSORT reporting guidelines and provide the checklist as supplementary material.
Explicitly following a reporting guideline enhances transparency and is often required by journals.
4.
MEDIUMreporting
In the Methods, clarify the blinding maintenance plan details, even though the trial is open-label, to address potential bias concerns.
Clarifying how bias was minimized in an open-label trial strengthens the design description.
5.
MEDIUMreporting
In the Results, consider reporting the number of patients with missing data for key endpoints to enhance transparency.
Missing data handling is a key aspect of trial reporting and is currently not detailed.
6.
MEDIUMreporting
In the Discussion, expand on the potential impact of the reduced tivozanib dose on efficacy, as it is a key limitation.
The reduced dose may have affected the primary endpoint, and a fuller discussion would help readers interpret the results.
7.
MEDIUMdata code
In the Data sharing statement, mention if the study protocol and statistical analysis plan are available publicly.
Providing access to the protocol and SAP increases transparency and reproducibility.
8.
MEDIUMreporting
In the Methods, provide more detail on the independent radiology review process, including how discordance was adjudicated.
Details on the independent review process are important for assessing endpoint reliability.
9.
MEDIUMreporting
In the Results, include a CONSORT flow diagram to show patient disposition clearly.
A flow diagram is a standard element of trial reporting and improves clarity.
10.
MEDIUMreporting
In the Discussion, avoid cross-study comparisons without emphasizing the limitations more strongly, as they are prone to bias.
Cross-trial comparisons are inherently biased and should be interpreted cautiously.
11.
LOWcopyedit
In the Abstract, Findings, change 'tivozanib' to 'tivozanib monotherapy' for consistency with the rest of the paper.
Consistent terminology avoids ambiguity about the comparator arm.
12.
LOWcopyedit
In the Discussion, paragraph 5, change 'unknow' to 'unknown'.
Corrects a typographical error.
13.
LOWcopyedit
In the Results, paragraph 4, rephrase the sentence about mPFS in the non-ICI group for clarity.
The current phrasing is awkward and could be misinterpreted.
14.
LOWcopyedit
In the Results, paragraph 3, remove the stray semicolon before the closing parenthesis in the HR reporting.
Fixes a punctuation error.

Full text (48,906 chars)Analyzed: Aug 16, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study.

Read full text (PMC)

DOI

10.1016/S0140-6736(24)01758-6

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/ee4f5f28-0e77-4f18-86da-31516ecc71e4" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/ee4f5f28-0e77-4f18-86da-31516ecc71e4/badge" alt="Kaimen Rigor review — 3.25★ (Adequate), 0 critical, 2 high issues for “Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

9a0763386a75ce5629a0eec14f087c9cdff8e953ab885783d3488ede8043a558

Verify via API

Issued Aug 16, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

3.25 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 2 reported means were read, and their group size is not stated where the values are printed. These checks need the count the mean was averaged over, so none was performed.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary endpoint is progression-free survival (PFS), a surrogate for overall survival. The paper does not demonstrate target engagement at the tested dose (no PK/PD data) and does not cite validated evidence linking PFS to overall survival in this specific post-ICI RCC setting. The efficacy claim is based on PFS, which is a surrogate.
“Primary endpoint was PFS by independent radiology review.”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The primary analysis shows no benefit of the combination (HR 1.10, p=0.49). The claim of tivozanib monotherapy efficacy is based on a median PFS of 7.4 months, but no anchor to a minimal clinically important difference or comparison to a clinically meaningful threshold is provided. The effect size is not explicitly anchored as clinically meaningful.
“mPFS was 5·7 months (95%CI, 4·04–7·43) with tivozanib–nivolumab and 7·4 months (5·55–9·23) with tivozanib (HR, 1·10; 95%CI, 0·84–1·43; p=0·49).”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 302OverreachOverstated conclusions 03AuthenticityNone found 104DisclosureReporting gaps 05AvailabilityNone found 06Copyedit5 minor suggestions

Numerical inconsistencies

1 finding · worst low

Internal contradictions in the reported numbersAssessed

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.

Overstated conclusions

3 findings · worst high

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

4 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

None found

Checked — nothing surfaced.

Reporting gaps

1 finding · worst medium

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior research on ICI rechallenge and tivozanib, and provides a logical rationale for the study.

Evidence

paraphrase[Introduction, paragraph 1-3]

“The negative outcome of CONTACT-03 left several questions unanswered, such as potential differences between anti–PD-1 and anti–PD-L1 therapies in the rechallenge setting...”

IntroductionFind in source

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise by citing prior research on ICI rechallenge and tivozanib efficacy, and provides a logical rationale for the study.

Evidence

Introduction ¶1Find in source

Introduction ¶3Find in source

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous with clear randomization, stratification, and a pre-specified statistical analysis plan, though it is open-label.

Evidence

MethodsFind in source

“The planned sample size of 326 patients with 191 events was intended to detect an improvement of 4 months or 50% and a hazard ratio of 0.67 with respect to the primary endpoint of PFS per IRR”

Statistical analysisFind in source

MethodsFind in source

PASSReviewer 2· 90% conf

The study design is rigorous for a phase 3 trial, with clear randomization, stratification, and a pre-specified primary endpoint, though it is open-label.

Evidence

MethodsFind in source

“The planned sample size of 326 patients with 191 events was intended to detect an improvement of 4 months or 50% and a hazard ratio of 0.67 with respect to the primary endpoint of PFS per IRR”

Statistical analysisFind in source

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and clinical characteristics are well reported, including sex, age, and race, which are adequate for a human trial.

Evidence

“Age (years) Mean (range) | 63·3 (37–87) | 62·2 (33–82) | | Sex, n (%) Male Female | 125 (73) 46 (27) | 134 (78) 38 (22)”

Table 1Find in source

“Race, n (%) White Asian Black or African American Not reported, other, or missing | 112 (65) 1 (<1) 2 (1) 56 (33) | 107 (62) 0 8 (5) 57 (33)”

Table 1Find in source

PASSReviewer 2· 90% conf

Biological variables are well reported for a human trial, including sex, age, and demographics.

Evidence

“Sex, n (%) Male Female | 125 (73) 46 (27) | 134 (78) 38 (22) |”

Table 1Find in source

“Race, n (%) White Asian Black or African American Not reported, other, or missing | 112 (65) 1 (<1) 2 (1) 56 (33) | 107 (62) 0 8 (5) 57 (33) |”

Table 1Find in source

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approvals and consent are adequately reported, including IRB approval and written informed consent.

Evidence

“the study protocol and all amendments were approved by independent review boards or ethics committees at each study site.”

MethodsFind in source

“All patients provided written informed consent prior to any screening or study procedures.”

MethodsFind in source

PASSReviewer 2· 90% conf

Ethical approvals and consent are adequately reported.

Evidence

“the study protocol and all amendments were approved by independent review boards or ethics committees at each study site.”

MethodsFind in source

“All patients provided written informed consent prior to any screening or study procedures.”

MethodsFind in source

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedNOT REPORTED

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational products (tivozanib and nivolumab) are identified with manufacturer and dosing, which is adequate for a drug trial.

Evidence

“Tivozanib was provided by the study sponsor (Aveo Pharmaceuticals, Inc.; Boston, MA, USA), and nivolumab was provided by Bristol Myers Squibb (Princeton, NJ, USA).”

MethodsFind in source

PASSReviewer 2· 90% conf

The investigational products are adequately identified, and no other key biological resources are used.

Evidence

“Tivozanib was provided by the study sponsor (Aveo Pharmaceuticals, Inc.; Boston, MA, USA), and nivolumab was provided by Bristol Myers Squibb (Princeton, NJ, USA).”

MethodsFind in source

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedNOT REPORTED

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and confidence intervals reported.

Evidence

“Treatment arms were compared using a stratified log-rank test with a two-sided 5% significance level.”

Statistical analysisFind in source

“The stratified hazard ratio was 1·10 (95% CI, 0·84–1·43; p=0·49)”

Results ¶2Find in source

“mPFS was 5·7 months (95%CI, 4·04–7·43) with tivozanib–nivolumab and 7·4 months (5·55–9·23) with tivozanib (HR, 1·10; 95%CI, 0·84–1·43; p=0·49).”

Results ¶2Find in source

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and confidence intervals reported.

Evidence

“Treatment arms were compared using a stratified log-rank test with a two-sided 5% significance level.”

Statistical analysisFind in source

“The stratified hazard ratio was 1·10 (95% CI, 0·84–1·43; p=0·49)”

Results ¶2Find in source

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 80% conf

A data sharing statement is present but vague, lacking specific platform details or conditions.

Evidence

“For eligible studies, qualified researchers may request access to individual patient-level clinical data through a data request platform.”

Data availabilityFind in source

WARNReviewer 2· 80% conf

A data sharing statement is present but vague, lacking a specific platform or conditions.

Evidence

“For eligible studies, qualified researchers may request access to individual patient-level clinical data through a data request platform.”

Data availabilityFind in source

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineNOT REPORTED

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The manuscript is transparent with trial registration, limitations discussed, and proportional conclusions.

Evidence

“The trial is registered with ClinicalTrials.gov (https://clinicaltrials.gov/) : NCT04987203 (https://clinicaltrials.gov/ct2/show/NCT04987203) .”

Statistical analysisFind in source

paraphrase[Discussion, paragraph 5]

“Funding Aveo Pharmaceuticals, Inc.”

FundingFind in source

PASSReviewer 2· 90% conf

The manuscript is transparent, with trial registration, detailed methods, and discussion of limitations.

Evidence

“The trial is registered with ClinicalTrials.gov (https://clinicaltrials.gov/) : NCT04987203 (https://clinicaltrials.gov/ct2/show/NCT04987203) .”

Statistical analysisFind in source

“There are, however, several limitations of the study to be recognized: (1) The reduced dose of tivozanib used to manage the potential increased toxicity in the combination arm. This choice may have impacted the efficacy reflected by the numerically lower median PFS in the combination arm. (2) The open-label study design is in principle more vulnerable to patient bias and placebo effects due to lack of blinding for both patients and investigators.”

Discussion ¶5Find in source

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 21 references by DOI: 19 verified — 2 no DOI (shown, not verified).

1 data/code link checked; 1 live.

Copyediting

5 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 5 minor suggestions below.

5 copyedit issues flagged: mostly consistency, typo, clarity.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
HIGHdata code
In the Data sharing statement, specify the data request platform (e.g., Vivli, YODA) and the conditions for access (e.g., proposal review, timeframe).
The current statement is vague and does not meet the standard for data availability, which is a common reviewer concern.
2.
HIGHstatistics
In the Methods, Statistical analysis, identify the statistical software and version used (e.g., SAS 9.4, R 4.0).
Naming the software improves reproducibility and is expected in clinical trial reporting.
3.
MEDIUMreporting
In the Methods or end of manuscript, state adherence to CONSORT reporting guidelines and provide the checklist as supplementary material.
Explicitly following a reporting guideline enhances transparency and is often required by journals.
4.
MEDIUMreporting
In the Methods, clarify the blinding maintenance plan details, even though the trial is open-label, to address potential bias concerns.
Clarifying how bias was minimized in an open-label trial strengthens the design description.
5.
MEDIUMreporting
In the Results, consider reporting the number of patients with missing data for key endpoints to enhance transparency.
Missing data handling is a key aspect of trial reporting and is currently not detailed.
6.
MEDIUMreporting
In the Discussion, expand on the potential impact of the reduced tivozanib dose on efficacy, as it is a key limitation.
The reduced dose may have affected the primary endpoint, and a fuller discussion would help readers interpret the results.
7.
MEDIUMdata code
In the Data sharing statement, mention if the study protocol and statistical analysis plan are available publicly.
Providing access to the protocol and SAP increases transparency and reproducibility.
8.
MEDIUMreporting
In the Methods, provide more detail on the independent radiology review process, including how discordance was adjudicated.
Details on the independent review process are important for assessing endpoint reliability.
9.
MEDIUMreporting
In the Results, include a CONSORT flow diagram to show patient disposition clearly.
A flow diagram is a standard element of trial reporting and improves clarity.
10.
MEDIUMreporting
In the Discussion, avoid cross-study comparisons without emphasizing the limitations more strongly, as they are prone to bias.
Cross-trial comparisons are inherently biased and should be interpreted cautiously.
11.
LOWcopyedit
In the Abstract, Findings, change 'tivozanib' to 'tivozanib monotherapy' for consistency with the rest of the paper.
Consistent terminology avoids ambiguity about the comparator arm.
12.
LOWcopyedit
In the Discussion, paragraph 5, change 'unknow' to 'unknown'.
Corrects a typographical error.
13.
LOWcopyedit
In the Results, paragraph 4, rephrase the sentence about mPFS in the non-ICI group for clarity.
The current phrasing is awkward and could be misinterpreted.
14.
LOWcopyedit
In the Results, paragraph 3, remove the stray semicolon before the closing parenthesis in the HR reporting.
Fixes a punctuation error.

Full text (48,906 chars)Analyzed: Aug 16, 2026